Fennec Pharmaceuticals Inc (FENC)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $410.25M
Last updated: Nov 17, 2026 at 11:05 AM ET
Fennec Pharmaceuticals Inc (FENC) Stock Forecast
Analysts expect Fennec Pharmaceuticals (FENC) to earn $0.35 per share in the fiscal year ending Dec 31, 2026, on revenue of $74.59M. Of 5 analysts, 5 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 4 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 5 ratings average 1.80, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 20.0% |
| Buy | 4 | 80.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 5
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 194.3% and revenue estimates rise 41.3%.
- Fiscal year ending Dec 31, 2026
- $0.35
- EPS consensus, revenue $74.59M
- Fiscal year ending Dec 31, 2027
- $1.03
- EPS consensus, revenue $105.38M
- Next report
- Mar 22, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.35 | $0.21 to $0.52 | 4 | $74.59M | $73.97M to $75.10M | 3 |
| Dec 31, 2027 | $1.03 | $0.73 to $1.42 | 4 | $105.38M | $99.60M to $110.57M | 5 |
Quarterly Estimates
The EPS consensus falls from $0.15 for the quarter ending Dec 31, 2026 to $0.12 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.15 | $0.09 to $0.24 | 8 | $21.93M | $19.46M to $23.63M | 8 |
| Mar 31, 2027 | $0.12 | $0.11 to $0.13 | 2 | $22.47M | $21.90M to $22.80M | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 8 upward and 4 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 4 | 1 |
| Fiscal year ending Dec 31, 2027 | 3 | 2 |
| Quarter ending Mar 31, 2027 | 1 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 6.1% from $0.33.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.35 | $0.32 | $0.32 | $0.32 | $0.33 | +4.0% |
| Fiscal year ending Dec 31, 2027 | $1.03 | $0.95 | $0.95 | $0.95 | $0.95 | +8.5% |
| Quarter ending Mar 31, 2027 | $0.12 | $0.11 | $0.11 | $0.11 | $0.11 | +9.1% |
Frequently Asked Questions About FENC
What is the FENC stock forecast?
Consensus analyst estimates put Fennec Pharmaceuticals's EPS at $0.35 for the fiscal year ending Dec 31, 2026, on revenue of $74.59M. The consensus rating from 5 analysts is Buy.
How do analysts rate FENC stock?
Of 5 analysts covering Fennec Pharmaceuticals, 1 rates it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from FENC next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.35, with estimates from $0.21 to $0.52 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $1.03, with estimates from $0.73 to $1.42 from 4 analysts.
What revenue do analysts expect from Fennec Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $74.59M, with estimates from $73.97M to $75.10M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $105.38M, with estimates from $99.60M to $110.57M.
How many analysts cover FENC?
5 analysts rate Fennec Pharmaceuticals stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
FENC pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors